Literature DB >> 12093965

The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy.

Ampaiwan Chuansumrit1, Pracha Nuntnarumit, Chusak Okascharoen, Sumete Teeraratkul, Saranya Suwansingh, Sarayut Supapannachart.   

Abstract

The case of a preterm infant weighing 1120 g who successfully received recombinant activated factor VII (rFVIIa) without complication for control of a life-threatening bleeding event resulting from a ruptured umbilical artery is reported. After performing an exploratory laparotomy at 27 hours of age, hemorrhage from the surgical wound and various sites persisted. By 63 hours of age, the infant had received a total of 192 mL (171 mL/kg) of packed red blood cells, 115 mL (103 mL/kg) of fresh frozen plasma, 8 mL of cryoprecipitate, and 75 mL (67 mL/kg) of platelet concentrate without stabilization. Hemorrhage ceased after 2 doses of 40 microg/kg/dose recombinant activated factor VII given at 63 and 70 hours of age, with subsequent stabilization of the hematocrit and without need for additional transfusion therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093965     DOI: 10.1542/peds.110.1.169

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa.

Authors:  Monika Girisch; Ralf Rauch; Roman Carbon; Thomas Habash; Michael Hofbeck
Journal:  Eur J Pediatr       Date:  2004-01-10       Impact factor: 3.183

2.  Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.

Authors:  Sunil Bhat; Satya Prakash Yadav; Madasu Anjan; Veronique Dinand; Anupam Sachdeva
Journal:  Indian J Pediatr       Date:  2011-02-17       Impact factor: 1.967

Review 3.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 4.  Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.

Authors:  Christian von Heymann; Sven Jonas; Claudia Spies; Klaus-Dieter Wernecke; Sabine Ziemer; Detlev Janssen; Jürgen Koscielny
Journal:  Crit Care       Date:  2008-02-15       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.